A randomised trial investigating the effect on biomedical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definite radiation treatment for localised carcinoma of the prostate (RADAR)

Six months of hormone treatment improves the results of radiotherapy for men with early prostate cancer. This trial will determine if adding another 12 months of hormone treatment after radiotherapy is even better. Bones are often affected by prostate cancer and can also be damaged by prolonged hormone treatment. Bisphosphonates are drugs that make bones stronger. This trial will also determine if treatment with a bisphosphonate can help prevent these bone problems.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

1071

Closing Date of Accrual

2007

Trial Chairperson

Prof Jim Denham, Calvary Mater Newcastle, NSW

Trial Contact

Allison.Steigler@newcastle.edu.au

Clinical Trial Registration

Related Post

World Radiotherapy Awareness Day promotion at ESTRO26
10 June, 2026

Global cancer community prepares to unite for 2026 World Radiotherapy Awareness Day

LATEST NEWS: 10 June 2026 The global radiation therapy

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research